Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/31/14 → 12/13/18 |
Funding
- Retrophin Incorporated: $11,644.00
Efficacy and Safety of RE-021, A Dual Endothelin Receptor and Angiotensin Receptor Blocker, In Patients with Focal Segmental Glomerulosclerosis(FSGS):A Randomized, Double-Blind, Active-Control, Dose Escalation Study
- Woroniecki, Robert (PI)
- Supe-Markovina, Katarina (CoPI)
Project: Research